Change search
ReferencesLink to record
Permanent link

Direct link
The association between endostatin and kidney disease and mortality in patients with type 2 diabetes
Show others and affiliations
2016 (English)In: Diabetes & Metabolism, ISSN 1262-3636, E-ISSN 1878-1780, Vol. 42, no 5, 351-357 p.Article in journal (Refereed) Published
Abstract [en]

AIM: Circulating endostatin, a biologically active derivate of collagen XVIII, is considered to be a marker of kidney disease and a risk factor for its related mortality. However, less is known of the role of endostatin in diabetes and the development of diabetic nephropathy. For this reason, our study investigated the associations between circulating endostatin and the prevalence and progression of kidney disease, and its mortality risk in patients with type 2 diabetes (T2D).

METHODS: This was a cohort study of 607 patients with T2D (mean age: 61 years, 44% women). Estimated glomerular filtration rate (eGFR), calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, was used to assess the patients' kidney function decline and mortality.

RESULTS: Of the total study cohort, 20 patients declined by ≥20% in eGFR over 4 years, and 44 died during the follow-up (mean duration: 6.7 years). At baseline, participants with diabetic nephropathy (defined as eGFR<60mL/min/1.73m(2)) and/or microalbuminuria [defined as a urinary albumin-to-creatinine ratio (ACR)>3g/mol] had higher median levels of endostatin than those without nephropathy (62.7μg/L vs 57.4μg/L, respectively; P=0.031). In longitudinal analyses adjusted for age, gender, baseline eGFR and ACR, higher endostatin levels were associated with a higher risk of decline (≥20% in eGFR, OR per 1 SD increase: 1.73, 95% CI: 1.13-2.65) and a higher risk of mortality (HR per 1 SD increase: 1.57, 95% CI: 1.19-2.07).

CONCLUSION: In patients with T2D, circulating endostatin levels can predict the progression of kidney disease and mortality independently of established kidney disease markers. The clinical usefulness of endostatin as a risk marker in such patients merits further studies.

Place, publisher, year, edition, pages
2016. Vol. 42, no 5, 351-357 p.
Keyword [en]
Albumin-to-creatinine ratio; Angiogenesis; Chronic kidney disease; Community; Extracellular matrix remodeling; NIDDM
National Category
Clinical Medicine
Research subject
Health and Welfare
URN: urn:nbn:se:du-21372DOI: 10.1016/j.diabet.2016.03.006PubMedID: 27080454OAI: oai:DiVA.org:du-21372DiVA: diva2:920561
Available from: 2016-04-18 Created: 2016-04-18 Last updated: 2016-11-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ärnlöv, Johan
By organisation
Medical Science
In the same journal
Diabetes & Metabolism
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 176 hits
ReferencesLink to record
Permanent link

Direct link